



**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

Serial No. 10/626,941  
Filing Date: 07/25/2003  
Examiner: Phyllis Spivack  
Group Art Unit: 1614  
Docket No. 01073/1

Date of Deposit: November 18, 2004

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

Fee Transmittal  
Information Disclosure Statement  
IDS Form 1449  
IDS References (39)  
Post Card

Michelle Becker  
(Typed or printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27TOTAL AMOUNT OF PAYMENT (\$)  
**\$180.00**

## Complete if Known

Application Number	10/626,941
Filing Date	7/25/2003
First Named Inventor	Manning et al
Examiner Name	Phyllis Spivack
Art Unit	1614
Attorney Docket No.	01073/1

## METHOD OF PAYMENT (check all that apply)

 Check  Credit card  Money Order  Other  None  
 Deposit Account:
Deposit Account Number **19-1025**Deposit Account Name **Pharmacia Corporation**

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1001	790	2001	395	Utility filing fee	
1002	350	2002	175	Design filing fee	
1003	550	2003	275	Plant filing fee	
1004	790	2004	395	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1) (\$)					

## 2. EXTRA CLAIM FEES FOR UTILITY AND

	Extra Claims	Fee from below	Fee Paid
Total Claims	-20** = 0	X 0 = 0.00	
Independent Claims	-3** = 0	X 0 = 0.00	
Multiple Dependent		=	

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	88	2201	44	Independent claims in excess of 3
1203	300	2203	150	Multiple dependent claim, if not paid
1204	88	2204	44	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)				<b>\$0.00</b>

\*\*or number previously paid, if greater; For Reissues, see above

## 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non - English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	430	2252	215	Extension for reply within second month	
1253	980	2253	490	Extension for reply within third month	
1254	1,530	2254	765	Extension for reply within fourth month	
1255	2,080	2255	1,040	Extension for reply within fifth month	
1401	340	2401	170	Notice of Appeal	
1402	340	2402	170	Filing a brief in support of an appeal	
1403	300	2403	150	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,370	2453	685	Petition to revive - unintentional	
1501	1,370	2501	685	Utility issue fee (or reissue)	
1502	490	2502	245	Design issue fee	
1503	660	2503	330	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR § 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Statement	<b>180.00</b>
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)					

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

**\$180.00**

## SUBMITTED BY

Name (Print/Type)	Philip B. Polster, II	Registration No. (Attorney/Agent)	43,864	Telephone	314-274-9094
Signature		Date	11/18/2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of )  
Manning, et al. ) Attorney Docket No. 01073/1  
)  
Serial No. 10/626,941 ) Group Art Unit: 1614  
)  
Filed: July 25, 2003 ) Examiner: Phyllis Spivack

For METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL  
CONDITIONS

November 18, 2004

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313


SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please charge the fee of \$180.00 to Deposit Account 19-1025. If any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

  
Philip B. Polster, II.  
Reg. No. 43,864  
Attorney for Applicants  
(314) 274-9094 (St. Louis)

Pharmacia Corporation  
Corporate Patent Department  
P.O. Box 1027  
Chesterfield, MO 63006

11/24/2004 EABUBAKI 00000098 191025 10626941  
01 FC:1806 180.00 DA



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 01073/1	APPLICATION NO.: 10/626,941	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Manning, et al.				
(Use several sheets if necessary)		Filed: 07/25/2003		Group: 1614		

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		4,769,498	08/06/98	Billing et al	568	454	02/09/87
		5,132,453	07/21/92	Griffith et al	562	560	03/22/91
		5,684,008	11/04/97	Hallinan et al	514	256	11/09/94
		5,830,917	11/03/97	Moore et al	514	634	09/11/95
		5,854,251	12/29/98	Hallinan et al	514	256	11/08/95
		5,863,931	01/26/99	Beams et al	514	357	12/23/92
		5,919,787	07/06/99	Hallinan et al	514	256	10/05/98
		5,945,408	08/31/99	Webber et al	514	63	08/08/96
		5,981,511	11/09/99	Gapud et al	514	63	03/05/97
		6,355,689	03/12/02	Beswick et al	514	665	05/27/99
		6,586,747	07/01/03	Webber et al	514	562	03/23/01

## FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
1	19541146	01/05/97	DE	C07D	233/84			X
2	19836697	24/02/00	DE	C07D	239/42			X
3	0446699	18/09/91	EP	C07K	5/06		X	
4	1295880	26/03/03	EP	C07D	403/12		X	
5	93/13055	08/07/93	PCT	C07K	257/14		X	
6	94/12165	09/06/94	PCT	A61K	31/155		X	
7	94/14780	07/07/94	PCT	C07D	239/48		X	
8	95/11014	27/04/95	PCT	A61K	31/155		X	
9	95/11231	27/04/95	PCT	C07D	207/22		X	
10	95/24382	14/09/95	PCT	C07C	257/14		X	
11	96/15120	23/05/96	PCT	C07D	257/06		X	
12	96/33175	24/10/96	PCT	C07D	223/12		X	
13	96/35677	14/11/96	PCT	C07D	223/12		X	
14	98/30537	16/07/98	PCT	C07C	323/58		X	
15	98/37079	27/08/98	PCT	C07D	403/04		X	
16	99/46240	16/09/99	PCT	C07C	257/14		X	
17	99/62875	09/12/99	PCT	C07C	323/58		X	
18	00/26195	11/05/00	PCT	C07D	257/06		X	
19	01/72703	04/10/01	PCT	C07C	323/58		X	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>FORM PTO-1449</b>	U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 01073/1	APPLICATION NO.: 10/626,941
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		INVENTOR: Manning, et al.	
(Use several sheets if necessary)		Filed: 08/02/02	Group:

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial		
20	Moncada, S. et al; FASEB J., Vol. 9, pp. 1319-1330, 1995.	
21	Ohtsuka et al; J. Pharmacol. Exp. Ther., Vol. 303, Issue 1, pp. 52-57, Oct. 2002.	
22	Jeanguenat et al; J. Chem. Soc. Perkin. Trans. 1, pp. 2291, 1991	
23	Pattenden et al; Tetrahedron, Vol. 49, pp. 2131, 1993	
24	Seebach, D. et al; Helvetica Chimia Acta, Vol. 68, 1243, 1985.	
25	Sasaki, Andre N. et al; Tetrahedron Lett. Vol. 21, pp. 4263, 1980.	
26	O'Donnell, Martain J.; J. Org. Chem., Vol. 47, pp. 2663, 1982.	
27	Jenmalm, Annika et al; J. Org. Chem., Vol. 59, pp. 1139-1148, 1994.	
28	Chinchilla, Rafael et al; Synthesis, Vol. 4, pp. 704-717, 1999	
29	Bredt et al; Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 682-685, 1990	
30	Moore et al; J. Med. Chem., Vol. 39, 669-672, 1996	
31	Rodi et al; In the Biology of Nitric Oxide, Pt. 4: Enzymology, Biochemistry and Immunology; Portland Press Ltd.; London, pp. 447-450, 1995	
32	Misko, T. P. et al; Analytical Biochemistry, Vol. 214, pp.11-16, 1993	
33	Young, Robert J. et al; Bioorganic & Medicinal Chemistry Letter, Vol. 10, No. 6, pp. 597-600, 2000, "Inhibition of Inducible Nitric Oxide Synthesis Acetamidine Derivates of Hetero-Substituted Lysine and Homolysine".	
34	McGill, J. M. et al; Gastroenterology, Vol. 6, No. 4, Part 2, pp. A1040, April 1999, XP008029524	
35	Alderton, W. et al; Acta Physiologica Scandinavica, Vol. 167, No. Suppl. 645, pp. 11, Sept. 1999, XP008029544, "GW274150 is a potent, long-acting, highly selective inhibitor of iNOS (NOS-2) with therapeutic potential in post-operative ileus".	
36	Blasko, Eric et al; The Journal of Biological Chemistry, Vol. 277, No. 1, pp. 295-302, Issue of Jan. 04, 2002, XP002276722, "Mechanistic Studies with Potent and Selective Inducible Nitric Oxide Synthase Dimerization Inhibitors"	
37	McMillan, Kirk et al; PNAS; Vol. 97, No. 4, pp. 1506-1511, Feb. 15, 2000, XP002938958, "Allosteric Inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry".	
38	Fitch, R. et al; Nitric Oxide, Vol. 4, No. 3, pp. 201, 2000, XP001189352, "Pharmacological selectivity and therapeutic potential of inducible nitric oxide synthase (iNOS) dimerization inhibitors".	
39	Ichinose, Fumito et al; Nitric Oxide, Vol. 6, No. 4, pp. 403, June 2002, XP001189350, " Selective iNOS dimerization inhibitors are efficacious in acute and chronic models of Inflammation and Immunity".	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	